Diabetes, Metabolic Syndrome and Obesity

We are pleased to announce a new hot-topic Article Collection in Diabetes, Metabolic Syndrome and Obesity dedicated to the game-changing role of GLP-1 receptor agonists in type 2 diabetes and obesity. Since their clinical introduction, GLP-1 receptor agonists have revolutionized patient care, offering significant benefits in glycemic control, weight loss and management, and cardiovascular and renal diseases for eligible patients. 

Given the recognized importance of GLP-1 agonists in managing type 2 diabetes and obesity, and the accumulating new evidence showing several pleiotropic effects, Diabetes, Metabolic Syndrome and Obesity invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies. 

The Collection, edited by the Editor-In-Chief Professor Rebecca Conway and the Section Editor Professor Ernesto Maddaloni, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. 

While the call is open to receive manuscripts across the broad spectrum of GLP-1 agonists in managing type 2 diabetes and obesity, the Editors are particularly interested in manuscripts relating to the following areas:

• Obesity
• Diabetes complications, particularly cardiovascular disease, nephropathy, diabetic bone disease
• The brain (reduction in cognitive decline, addition) in diabetes
• Pediatric obesity and diabetes or type 1 diabetes

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code BOUZT.

The deadline for submitting manuscripts is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Co-occurring Obesity and Eating Disorders: Challenges, Mechanisms, and Intervention Strategies" in Diabetes, Metabolic Syndrome and Obesity.

Obesity and eating disorders often occur together, creating complex clinical profiles that challenge conventional treatment approaches. While obesity is most frequently associated with binge-eating disorder, it may also coexist - albeit less commonly - with bulimia nervosa, night eating syndrome, and atypical anorexia nervosa. In some cases, obesity develops before the eating disorder, functioning as a potential risk factor; in others, it emerges as a consequence of eating disorders. A striking aspect of this comorbidity is the marked gender disparity, with women disproportionately affected compared to men. The coexistence of these conditions is linked to heightened medical complications, greater psychological distress, and diminished quality of life. Shared biological, psychological, and sociocultural mechanisms likely play a role in their onset and persistence, while stigma, diagnostic overshadowing, and fragmented healthcare pathways often delay recognition and impede effective, integrated treatment.

Despite its significant clinical and public health implications, the coexistence of obesity and eating disorders remains under-recognized and under-researched. Many patients present with overlapping symptoms that do not fit neatly into traditional diagnostic categories, leading to misdiagnosis or delayed intervention. This gap in recognition can exacerbate both physical and mental health outcomes, increasing the risk of type 2 diabetes, cardiovascular disease, and severe psychiatric comorbidities. The lack of integrated treatment models means that obesity and eating disorders are often addressed separately, resulting in fragmented care that fails to address the interplay between them. Increased awareness and targeted research are essential to understand shared risk factors better, develop practical screening tools, and design multidisciplinary treatment strategies. Addressing this comorbidity could significantly improve long-term health outcomes, reduce stigma, and promote more effective prevention and intervention efforts in both obesity and eating disorder care.

This Collection invites submissions that explore the intersection of obesity and eating disorders within the context of metabolic health, psychological well-being, and clinical care. Relevant topics include epidemiological studies on prevalence and risk factors; research on shared biological pathways; the influence of sociocultural and environmental determinants; and the role of stigma and weight bias in clinical outcomes. It also welcomes studies evaluating screening tools, diagnostic criteria, and integrated treatment models, particularly those that address both physical and psychological aspects. Articles examining the impact of comorbidity on diabetes risk, glycaemic control, and other obesity-related complications are especially encouraged. The Collection will consider a range of formats, including original research articles, systematic reviews, meta-analyses, clinical case studies, and perspectives from multidisciplinary teams. By fostering cross-disciplinary dialogue, this initiative aims to advance understanding and improve prevention, early detection, and treatment strategies for individuals affected by both obesity and eating disorders.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your manuscript on our website, entering the promo code 190D6 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 May 2026.

Guest Advisor

Dr. Riccardo Dalle Grave, Villa Garda Hospital, Italy

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Behavioral and Psychosocial Aspects in the Management and Treatment of Diabetes and Obesity" in Diabetes, Metabolic Syndrome and Obesity.

Diabetes and obesity remain major challenges for modern societies, not only because of their rising prevalence but also due to the substantial burden they place on people living with these conditions and their families. Although medical care has advanced significantly—with new medications, improved insulin formulations, and modern technologies—clinical outcomes often remain suboptimal. Increasing evidence highlights that behavioral and psychosocial factors play a crucial role in the effectiveness of treatment and long-term outcomes. Psychological functioning, self-management behaviors, emotional distress, and social context interact with biological and medical factors in shaping the course of diabetes and obesity.

It seems unlikely that progress in managing diabetes and obesity will result from identifying a single crucial factor. Rather, improvement is expected to come from recognizing and addressing a range of contributing factors.

Despite remarkable progress in pharmacotherapy and technological innovations, many individuals still experience challenges achieving optimal disease management. Behavioral barriers, psychosocial burden, and difficulties in sustaining effective self-management remain major contributors to unmet needs in diabetes and obesity care. Improving behavioral and psychosocial support may therefore represent one of the most transformative avenues for enhancing treatment outcomes. This Article Collection aims to gather studies that deepen understanding of behavioral and psychosocial mechanisms and translate this knowledge into practical strategies that can improve management, adherence, and quality of life.

This Collection focuses exclusively on behavioral and psychosocial aspects relevant to the management and treatment of diabetes and obesity. We particularly welcome submissions addressing:

• Behavioral determinants of diabetes and obesity management: self-care behaviors, adherence, lifestyle patterns, motivation, decision-making, and behavioral interventions.
• Psychosocial mechanisms influencing the course and treatment of diabetes and obesity: emotional distress, coping styles, well-being, social support, stigma, self-efficacy, illness perceptions.
• Behavioral and psychosocial aspects of technology use: psychological adaptation to diabetes technologies, human-technology interaction, digital burden, digital literacy, and the impact of technology on self-management behaviors.
• Interventions integrating behavioral and psychosocial components: structured education, psychotherapy, digital behavioral programs, and multidisciplinary approaches.
• Psychosocial and behavioral dimensions of obesity as a risk factor for diabetes: lifestyle behaviors, weight-related distress, family and social influences.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, entering the promo code 503C6 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 30 September 2026.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Kokoszka Andrzej, The Medical University of Warsaw, Poland

[email protected]

Tomasz Klupa, Department of Metabolic Diseases Jagiellonian University Medical College, Poland

[email protected]

Katarzyna Cyranka, Unit of Psychodiabetology, Department of Metabolic Diseases Jagiellonian University Medical College

Department of Psychiatry Jagiellonian University Medical College, Poland

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Real World Evidence for the Pharmacological Treatment of Diabetes: From Clinical Trials to Routine Practice" in Diabetes, Metabolic Syndrome and Obesity.

Diabetes mellitus represents one of the most pressing global health challenges of the 21st century, affecting over 500 million adults worldwide. The pharmacological landscape for diabetes has expanded rapidly, with the introduction of incretin-based therapies, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dual-acting agents alongside established glucose-lowering drug classes. While randomized controlled trials (RCTs) remain the gold standard for evaluating therapeutic efficacy, their strict inclusion criteria, controlled settings, and limited follow-up durations often restrict the generalizability of findings to diverse, real-world patient populations. Real world evidence (RWE), derived from electronic health records, claims databases, patient registries, and post-marketing surveillance, has emerged as an essential complement to RCT data for evaluating how antidiabetic pharmacotherapies perform in routine clinical practice. This Article Collection aims to present the latest advances in RWE research specifically pertaining to the pharmacological treatment of diabetes, ultimately informing evidence-based prescribing and clinical decision-making.

The importance of RWE for antidiabetic pharmacotherapy cannot be overstated. Despite the growing number of glucose-lowering agents available, significant gaps persist between the outcomes observed in clinical trials and those achieved in everyday practice. Patient adherence to prescribed regimens, treatment persistence over time, individualized glycemic targets, and the influence of polypharmacy and comorbidities all shape therapeutic outcomes in ways that RCTs cannot fully capture. Furthermore, regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency increasingly incorporate RWE into their drug approval and post-marketing evaluation frameworks, recognizing its value in supplementing trial-based efficacy data. Understanding how specific antidiabetic drug classes and treatment sequences perform across diverse ethnicities, age groups, and comorbidity profiles is essential for optimizing individualized prescribing strategies, improving glycemic control, and reducing treatment-related adverse events in the real-world setting.

This Article Collection invites original research articles, systematic reviews, meta-analyses, and narrative reviews that utilize real world data to evaluate the pharmacological treatment of diabetes. Topics of interest include, but are not limited to: the effectiveness and safety of emerging and established glucose-lowering agents in routine clinical practice; comparative effectiveness studies of antidiabetic drug classes, including SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin formulations, across diverse patient populations; real world treatment patterns, prescribing trends, and therapeutic sequencing strategies; the impact of medication adherence and persistence on glycemic control and long-term clinical outcomes; safety profiles and tolerability of antidiabetic pharmacotherapies as observed in post-marketing surveillance and pharmacovigilance databases; and health economic analyses and cost-effectiveness evaluations of glucose-lowering therapies derived from real world data sources. Contributions should align with the scope of Diabetes, Metabolic Syndrome and Obesity.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, entering the promo code E00B9 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 December 2026.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Yun Shen, Pennington Biomedical Research Center, USA

[email protected]

Prof. Gang Hu, Pennington Biomedical Research Center, USA

[email protected]

View all papers in this article collection